Notizie AIOM – anno XVII n. 711
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. ...Leggi tutto
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves ...Leggi tutto
FDA Grants Pembrolizumab Priority Review for Advanced SCLC
February 20, 2019 - The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for pembrolizumab as a treatment for patients with advanced small cell lung cancer (SCLC) whose disease has progressed following ≥2 prior lines ...Leggi tutto
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer
Patients with HIV infection are at increased risk for cancer. Cancer is the leading cause of death among non–AIDS-defining illnesses in these patients. Immune checkpoint inhibitor (ICI) therapy has transformed the treatment of cancer. However, clinical trials of ICIs ...Leggi tutto
Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM
Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, firmate da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici ...Leggi tutto
Dal Soroptimist International Club Genova a favore delle ragazze STEM
Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: ...Leggi tutto